JAMDA
Volume 8, Issue 8 , Pages 502-510 , October 2007

Optimizing Insulin Use in Type 2 Diabetes: Role of Basal and Prandial Insulin in Long-Term Care Facilities

  • Linda B. Haas, PhC, RN, CDE

      Affiliations

    • Corresponding Author InformationAddress correspondence to Linda Haas, PhC, RN, CDE, VA Puget Sound Health Care System, University of Washington School of Nursing, 1660 S. Columbian Way (S-118), Seattle, WA 98108–1597.

References 

  1. Travis SS, Buchanan RJ, Wang S, et al. Analyses of nursing home residents with diabetes at admission. J Am Med Dir Assoc. 2004;5:320–327
  2. Duffy RE, Mattson BJ, Zack M. Comorbidities among Ohio’s nursing home residents with diabetes. J Am Med Dir Assoc. 2005;6:383–389
  3. Russell LB, Valiyeva E, Roman SH, et al. Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care. 2005;28:1611–1617
  4. Mayfield JA, Deb P, Potter DEB. Diabetes and long-term care. In:  Harris MI,  Cowie CC,  Stern MP, et al. editor. Diabetes in America. 2nd ed.. Bethesda: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2004;
  5. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30(Suppl 1):S4–S41
  6. Centers for Disease Control and Prevention. Data & trends. National diabetes surveillance system. Prevalence of diabetes: Prevalence of diagnosed diabetes by age, United States, 1980–2005. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/figbyage.htm. Accessed July 23, 2007.
  7. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care. 1998;21:296–309
  8. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917–932
  9. Smith SA, Cabanala RL, Anderson SS, et al. Cost of glycemic control in long term care. Diabetes. 2006;54(Suppl 1):A1–A733
  10. Ashkenazy R, Abrahamson MJ. Medicare coverage for patients with diabetes (A national plan with individual consequences). J Gen Intern Med. 2006;21:386–392
  11. Miller DK, Lui L-YL, Perry HM, et al. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol A Biol Sci Med Sci. 1999;54A:M230–M236
  12. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–412
  13. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393
  14. Konzem SL. Optimization of treatment of type 2 diabetes in the elderly. US Pharmacist. 2000;25:Available at: http://www.uspharmacist.com/oldformat.asp?url=newlook/files/Feat/SrConsultcfm.cfm&pub_id=8&article_id=621. Accessed July 23, 2007.
  15. Katakura M, Naka M, Kondo T, et al. Normal mortality in the elderly with diabetes under strict glycemic and blood pressure control: Outcome of a 6-year prospective study. Diabetes. 2005;54(Suppl 1):A733
  16. Gilmer TP, O’Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847–1853
  17. Gilmer TP, O’Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28:59–64
  18. Zarowitz BJ, Tangalos EG, Hollenack K, et al. The application of evidence-based principles of care in older persons (issue 3): Management of diabetes mellitus. J Am Med Dir Assoc. 2006;7:234–240
  19. Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci. 2005;60:1157–1162
  20. Weinrebe W, Güneysu S, Welz-Barth A. Low muscle mass of the thigh is significantly correlated with delirium and worse functional outcome in older medical patients. J Am Geriatr Soc. 2002;50:1310–1311
  21. Morley JE. Is weight loss harmful to older men?. Aging Male. 2006;9:135–137
  22. Allsworth JE, Toppa R, Palin NC, et al. Racial and ethnic disparities in the pharmacologic management of diabetes mellitus among long-term care facility residents. Ethn Dis. 2005;15:205–212
  23. Shubrook JH, Gau J-T. Diabetes management in the extended care setting. Diabetes. 2006;54(Suppl 1):733
  24. Berry RM, Hunt Raleigh ED. Diabetic foot care in a long-term facility. J Gerontol Nurs. 2004;30:8–13
  25. Tariq SH, Karcic E, Thomas DR, et al. The use of a no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Diet Assoc. 2001;101:1463–1466
  26. Health Care Financing Administration (HCFA). Report to Congress: Appropriateness of Minimum Nurse Staffing Ratios in Nursing Homes. Baltimore: Centers for Medicare & Medicaid Services; 2000;
  27. US Pharmacopeia. USP Patient Safety CAPSlink. USP Center for the Advancement of Patient Safety; 2003;July
  28. Benbow SJ, Walsh A, Gill GV. Diabetes in institutionalised elderly people: A forgotten population?. BMJ. 1997;314:1868–1869
  29. Meneilly GS. Pathophysiology of type 2 diabetes in the elderly. Clin Geriatr Med. 1999;15:239–253
  30. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders With Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(Suppl 5):S265–S280
  31. Hagemann R, Sartory G, Hader C, et al. Mood and cognitive function in elderly diabetic patients living in care facilities. Dement Geriatr Cogn Disord. 2005;19:369–375
  32. Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging. 2005;22:209–218
  33. Gaede P, Pedersen O. Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: What are we waiting for?. Horm Metab Res. 2005;37(Suppl 1):76–82
  34. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012
  35. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  36. Cleveland JC, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium (Two paradoxes revisited). Circulation. 1997;96:29–32
  37. Graal MB, Wolffenbuttel BHR. The use of sulphonylureas in the elderly. Drugs Aging. 1999;15:471–481
  38. Sakharova OV, Inzucchi SE. Treatment of diabetes in the elderly (Addressing its complexities in this high-risk group). Postgrad Med. 2005;118:19–29
  39. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000;35:500–505
  40. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6:47–53
  41. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–263
  42. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–335
  43. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complications. 2002;16:123–132
  44. Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm. 2006;63:929–938
  45. Januvia. [prescribing information] Whitehouse Station, NJ: Merck & Co., Inc; 2006;
  46. Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at β-cells. Horm Metab Res. 1996;28:464–468
  47. Quast U, Stephan D, Bieger S, et al. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes. 2004;53(Suppl 3):S156–S164
  48. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111–3116
  49. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years (UK Prospective Diabetes Study (UKPDS) Group). Diabet Med. 1998;15:297–303
  50. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995–1000
  51. Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:737–745
  52. Dailey GE, Noor MA, Park J-S, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med. 2004;116:223–229
  53. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554–559
  54. Dailey G. A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Formulary. 2005;40:114–130
  55. Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther. 2004;26:889–901
  56. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(Suppl 3):S18–S24
  57. Leslie CA, Satin-Rapaport W, Matheson D, et al. Psychological insulin resistance: A missed diagnosis?. Diabetes Spectrum. 1994;7:52–57
  58. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy: The basis of patient reluctance. Diabetes Care. 1997;20:292–298
  59. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:9S–18S
  60. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681–1686
  61. Ben-Ami H, Nagachandran P, Mendelson A, et al. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med. 1999;159:281–284
  62. Garber AJ, Kim H, Santiago OM. Lower risk of hypoglycemia with insulin detemir vs NPH insulin in elderly people with type 2 diabetes: A pooled analysis of phase 3 trials. Diabetes. 2005;54(Suppl 1):A118
  63. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568–1573
  64. Pandya N. Diabetes management in long-term care. Caring for the Ages. 2003;4:21–24
  65. Schultes B, Baron M, Bremer JP, et al. Reduced awareness of hypoglycaemia in elderly patients with type 2 diabetes. Diabetes. 2005;54(Suppl 1):A1–A733
  66. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–2148
  67. Levemir [package insert]. Princeton, NJ: Novo Nordisk Inc, 2005.
  68. Lantus [package insert]. Kansas City: sanofi-aventis U.S. L.L.C., 2006.
  69. Rosenstock J, Wyne K. Insulin treatment in type 2 diabetes. In:  Goldstein BJ,  Müller-Wieland D editor. Textbook of Type 2 Diabetes. London: Martin Dunitz Ltd, a member of the Taylor & Francis Group; 2003;p. 131–154
  70. Apidra [package insert]. Kansas City: Aventis Pharmaceuticals Inc., 2005.
  71. Humalog [package insert]. Indianapolis: Eli Lilly and Company, 2004.
  72. Novolin R [package insert]. Princeton, NJ: Novo Nordisk Inc., 2005.
  73. NovoLog [package insert]. Princeton, NJ: Novo Nordisk Inc., 2005.
  74. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107–1112
  75. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: An assessment of treatment flexibility. Horm Metab Res. 2006;38:172–177
  76. Hamann A, Matthaei S, Rosak C, et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738–1744
  77. Riddle MC, Rosenstock J, Gerich J, et al. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086
  78. Halter JB, Kennedy L, Herman WH, et al. Glycemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C Study. Diabetes. 2006;55(Suppl 1):A1–A733
  79. Kennedy L, Herman WH, Strange P, et al. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1C on glycemic control in patients with type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1–8
  80. Karl DM. The use of bolus insulin and advancing insulin therapy in type 2 diabetes. Curr Diab Rep. 2004;4:352–357
  81. Janka HU, Plewe G, Busch K, et al. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in elderly patients with type 2 diabetes. Diabetes. 2005;54(Suppl 1):A1–A733
  82. Bindra S, Cefalu WT. Exubera (Inhale therapeutic systems). Curr Opin Investig Drugs. 2002;3:758–762
  83. Rathmann W, Haastert B, Icks A, et al. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994–2004. Diabetes Care. 2007;30:848–853
  84. Palmer AJ, Valentine WJ, Ray JA, et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin. 2007;23:895–901
  85. Brändle M, Azoulay M, Greiner R-A. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2007;45:203–220
  86. Zhang Q, Menditto L. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample. Am J Ther. 2005;12:337–343
  87. Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm. 2003;9:309–316
  88. Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005;21:291–298
  89. Byetta [package insert]. San Diego: Amylin Pharmaceuticals, Inc., 2005.
  90. Gryskiewicz KA, Coleman CI. Exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes. Formulary. 2005;40:86–90
  91. Symlin injection [package insert]. San Diego: Amylin Pharmaceuticals, Inc., 2005.
  92. Frias J, Lush C, Kesty N, et al. Efficacy and safety of pramlintide in insulin-using elderly patients with type 2 diabetes. Diabetes. 2006;55(Suppl 1):A1–A733
  93. Brandle M, Zhou H, Smith BRK, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26:2300–2304
  94. Gilman JA. A quality improvement project for better glycemic control in hospitalized patients with diabetes. Diabetes Educ. 2001;27:541–546

 I have served on a diabetes advisory board for sanofi-aventis U.S. from 2004 to the present and hold stock in Amylin Pharmaceuticals. I have no other financial interest in any product discussed in the manuscript.

 Editorial support has been provided by sanofi-aventis U.S.

PII: S1525-8610(07)00353-2

doi: 10.1016/j.jamda.2007.08.002

JAMDA
Volume 8, Issue 8 , Pages 502-510 , October 2007

Article Tools